Close menu




Biotech

Photo credits: pixabay.com

Commented by Armin Schulz on November 6th, 2023 | 06:45 CET

BioNTech and Bayer under pressure - Defence Therapeutics, on the other hand, with good results. Where is it worth investing?

  • Biotechnology
  • Pharma

There are currently big losers in the pharma and biotech sector among the companies that were the biggest beneficiaries of the Coronavirus Crisis. Sales at Pfizer/BioNTech are plummeting, and the entire sector is under pressure. In addition, there are patent disputes and increasing cost pressures from health insurance companies, especially in Europe. There are also high bureaucratic hurdles in the EU, meaning that more and more specialists prefer to emigrate to North America. Bayer's pharmaceuticals division is doing well, but the Company is struggling with the legal disputes surrounding the Monsanto takeover. In contrast to the first two companies mentioned, the news from Defence Therapeutics is consistently positive. We examine where it is worth getting in.

Read

Commented by Fabian Lorenz on November 1st, 2023 | 06:10 CET

More than 300% share price opportunity: BioNTech, Morphosys and Cardiol Therapeutics

  • Biotechnology
  • CBD

Study results, along with acquisitions by Big Pharma, are the drivers of biotech company share prices. However, in the current challenging stock market environment, even positive data can be overlooked. But this opens up opportunities for investors with a little more staying power. Sooner or later, the information is recognized, and stock prices rise, or a pharmaceutical giant makes a move. At BioNTech, for example, the price reaction to the long-awaited news from the cancer pipeline has failed to materialize. Analysts are also cautious. Cardiol Therapeutics is a different story. The Canadians have taken on the fight against heart disease and are making significant progress in their research. The share had more than doubled to EUR 1.08 by the summer. Several analysts see the current setback as a buying opportunity. Experts are also giving the thumbs up to German biotech pioneer Morphosys.

Read

Commented by Juliane Zielonka on October 27th, 2023 | 07:00 CEST

Porsche share, Globex Mining, Bayer AG - Who offers the most profitable return?

  • Mining
  • Gold
  • Biotechnology
  • Electromobility

Despite good figures, economic turbulence in the major customer China continues to make Porsche cautious about its forecasts for the coming year. The situation is quite different for the explorer Globex Mining, which has a mineral property with the valuable raw material vanadium in its portfolio. Vanadium is used in nuclear power plants, aircraft and spacecraft. Its 1% interest in a mineral property that can generate an expected annual free cash flow of USD 235 million for the next 21 years puts it in a good position. The net present value in this account from the interest is also positive. Bayer, on the other hand, has lost another glyphosate lawsuit. Find out what is so significant about this case here.

Read

Commented by André Will-Laudien on October 26th, 2023 | 08:15 CEST

Omicron or Pirola? Biotech shows doubling opportunities again! BioNTech, Pfizer, Defence Therapeutics, MorphoSys in focus

  • Biotechnology

We had ticked off the Corona pandemic long ago. But if you ask your acquaintances, you may find one or two who have recently been infected with the "Pirola" variant. The official code of the virus variant is BA.2.86, and it was first discovered in Israel. The current infections are spreading rapidly across Europe and have also reached Germany. So far, the new Omicron offshoot appears less contagious than its predecessors. The new symptoms associated with "Pirola" include skin rashes, diarrhea, changes in the mouth and tongue, itchy eyes and surprisingly, sore fingers or toes. What is going on here? It is a reason to look again at BioNTech and some other biotechs. Where are the opportunities lurking?

Read

Commented by Stefan Feulner on October 25th, 2023 | 07:20 CEST

BioNTech, Cardiol Therapeutics, Paion - Rising Attractiveness and Lots of Movement

  • Biotechnology
  • Innovations
  • Technology

The current geopolitical uncertainties with escalating conflicts in Ukraine and Israel, as well as fears of recession with continued high inflation, have also impacted the capital-intensive biotech sector. In the past week, the Nasdaq Biotech Index fell to its lowest level of the year. Since the beginning of the year, the loss amounts to almost 12%. This level should offer excellent entry opportunities for long-term investors, as many biotech companies are currently very well-positioned and attractively valued.

Read

Commented by Armin Schulz on October 17th, 2023 | 07:00 CEST

BioNTech, Cardiol Therapeutics, Bayer - Redefining the frontiers of medicine

  • Biotechnology
  • Pharma
  • heartdisease

The biotech and pharmaceutical sector is playing an increasingly important role in our society. This can be attributed primarily to demographic change, as people worldwide are getting older and older. As life expectancy increases, so does the prevalence of age-related diseases such as cancer and heart disease. These two disease categories place a significant burden on healthcare systems and require innovative solutions for diagnosis, treatment and prevention. After Corona, this could be where the next global blockbuster is developed. We look at three interesting candidates.

Read

Commented by Stefan Feulner on October 16th, 2023 | 06:50 CEST

Lots of activity in the biotech sector - Novo Nordisk, Defence Therapeutics, Morphosys

  • Biotechnology
  • Pharma
  • Innovations

Despite the rather gloomy economic outlook on the one hand and high interest rates on the other, there is significant movement in the capital-intensive biotechnology sector. After Amgen successfully concluded the acquisition of Horizon Therapeutics for USD 116.50 per share or a total volume of around USD 27.8 billion, further investments by Big Pharma in innovative and promising technologies will likely follow soon.

Read

Commented by Fabian Lorenz on October 11th, 2023 | 08:10 CEST

Attention Price Jump! Tui, Plug Power and Defence Therapeutics with News

  • Biotechnology
  • Innovations
  • Technology
  • Travel

Alarm at Tui and Deutsche Lufthansa. Both stocks are influenced by the terrorist attack in Israel this week. While the oil price is surging, aviation and tourism stocks are declining. The Tui share had already been trending weakly before. Even the leap into the profit zone could not change this. And what do analysts say? Meanwhile, Defence Therapeutics shone with positive news on a cancer therapy. As a result, the biotech share gained yesterday, offering further potential for price increases. Plug Power's share price rose by a good 7% yesterday. What is behind this?

Read

Commented by Fabian Lorenz on October 5th, 2023 | 07:10 CEST

Buy biotech stocks now? BioNTech, Morphosys and Cardiol Therapeutics in check

  • Biotechnology
  • Pharma

In times of high interest rates, the wheat is separated from the chaff, even in the biotech sector. After all, young research-based companies, in particular, have a high demand for capital. But at the moment, all companies are being lumped together. This opens up clear buying opportunities because some have full coffers. BioNTech belongs to this group. Thanks to the COVID-19 vaccine, research is fully financed. The same goes for Cardiol Therapeutics. The share of the Canadians is one of the summer's high flyers, and the recent price setback offers an entry opportunity. The analysts' price target is over 300% above the current level. And what do analysts say about the German biotech veteran Morphosys? Goldman Sachs has tripled its price target.

Read

Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

  • Biotechnology
  • Pharma
  • Investments

According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

Read